Skip to main navigation
Skip to main content
  • Investors & Media
    • Overview
    • Newsroom
    • Events
    • Financial Information
    • Stock Information & Analyst Coverage
    • FAQs
  • Careers
  • Partnerships & Business Development
  • Contact Us
  • Investors & Media
    • Overview
    • Newsroom
    • Events
    • Financial Information
    • Stock Information & Analyst Coverage
    • FAQs
  • Our Company
    • The Esperion Story
    • Leadership Team
    • Board of Directors
    • Ethics and Compliance
    • Corporate Governance & Committee Composition
  • Patients
    • Cholesterol Education
    • Unmet Need
    • Patient Advocacy and Resources
  • Products
  • Science
    • Pipeline
    • Clinical Trials
    • Expanded Access
    • Grants
/investor-relations/newsroom

Newsroom

Esperion announces results from Phase 1 study and four preclinical studies for ETC-1002
May 02, 2011
Esperion announces results from Phase 1 study and four preclinical studies for ETC-1002
Esperion Therapeutics Initiates Phase 2 Clinical Study for ETC-1002
Jan 06, 2011
Esperion Therapeutics Initiates Phase 2 Clinical Study for ETC-1002
TransGenRx Protein Therapeutics Technology to Support Research Related to Protein-Based HDL Therapies at Esperion Therapeutics
Jun 21, 2010
TransGenRx Protein Therapeutics Technology to Support Research Related to Protein-Based HDL Therapies at Esperion Therapeutics
Esperion Therapeutics and Cleveland Clinic Establish Collaboration for Research Related to HDL Therapies
Jun 14, 2010
Esperion Therapeutics and Cleveland Clinic Establish Collaboration for Research Related to HDL Therapies
Esperion Therapeutics Initiates Phase I Clinical Study for ETC-1002
Nov 15, 2009
Esperion Therapeutics Initiates Phase I Clinical Study for ETC-1002

Pagination

  • First page « first
  • Previous page ‹ previous
  • …
  • Page 50
  • Page 51
  • Page 52
  • Page 53
  • Page 54
  • Page 55
  • Page 56
  • Current page 57
  • Page 58
  • Next page next ›
  • Last page last »

-

Media Information

To speak with a member of our PR team, or to schedule an interview, please contact Esperion Corporate Communications by phone at +1 734-864-6774, or by email at corporateteam@esperion.com.

Leadership Information

Page Tools

Our Company

  • Our Company
    • The Esperion Story
    • Leadership Team
    • Board of Directors
    • Ethics and Compliance
    • Corporate Governance & Committee Composition

Patients

  • Patients
    • Cholesterol Education
    • Unmet Need
    • Patient Advocacy and Resources

Products

  • Products

Science

  • Science
    • Pipeline
    • Clinical Trials
    • Expanded Access
    • Grants

Careers

  • Careers

Partnerships & Business Development

  • Partnerships & Business Development

Investors & Media

  • Investors & Media
    • Overview
    • Newsroom
    • Events
    • Financial Information
    • Stock Information & Analyst Coverage
    • FAQs

Contact Us

  • Contact Us

All trademarks and trade names are the property of their respective owners.

© 2022 Esperion Therapeutics, Inc. All rights reserved. 05/20 US-CRP-2000082

Utility

  • Privacy Policy
  • Terms of Use
  • Accessibility Statement
  • Social Media Community Guidelines

Search

Share this page